Afatinib plus chemo for unresectable stage III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether combining afatinib (a targeted pill for EGFR mutations) with chemotherapy can shrink advanced stage III non-small cell lung cancer (NSCLC) enough to make surgery possible. It is for people whose cancer has not been treated yet and has a specific EGFR mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III non-small cell lung cancer that doctors cannot remove with surgery
- Your tumor has an EGFR mutation (a specific genetic change) found by a blood or tissue test
- You are physically active and able to care for yourself (ECOG score 0 or 1)
- You have at least one tumor that can be measured on scans
- Your kidneys, liver, and bone marrow are working well enough
- You have not had prior chemotherapy or radiation for this lung cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether removing the main lung tumor with surgery, combined with an EGFR-targeted pill, can help people with stage IV lung cancer that has a specific EGFR mutation. The goal is to improve outcomes compared with medication alone.
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
This trial tests a newer type of EGFR targeted therapy pill for people with advanced non-small cell lung cancer who have not had prior treatment and whose cancer has a specific genetic change called a PACC mutation. The goal is to see if the drug works well for this group.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.